Enochian Biosciences, Inc. – NASDAQ:ENOB

Add to watchlist

Market closed

Open in 1 day

+9.38%

month

-42.15%

quarter

-75.00%

year

Market Cap	45.38M
Enterprise value	68.94M

P/E	-0.53
EV/Sales	N/A
EV/EBITDA	-0.63
Price/Sales	N/A
Price/Book	0.98
PEG ratio	N/A
EPS	N/A

Revenue	N/A
EBITDA	-30.65M
Income	-38.38M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Enochian Biosciences, Inc. (NASDAQ:ENOB): Profit margin
Mar 2021	0	-4.03M
Jun 2021	0	-17.36M
Sep 2021	0	-10.41M
Dec 2021	0	-6.58M

Enochian Biosciences, Inc. (NASDAQ:ENOB): Debt to assets
Mar 2022	180100613	18.85M	10.47%
Jun 2022	84632663	12.01M	14.2%
Sep 2022	83070556	12.74M	15.34%
Dec 2022	80273663	13.37M	16.66%

Enochian Biosciences, Inc. (NASDAQ:ENOB): Cash Flow
Sep 2013	-9.70K	0	9.48K
Dec 2013	-16.84K	13.21K	3.65K
Mar 2020	-3.83M	-41.69K	6.2M
Jun 2020	-2.24M	-10.44K	0

Enochian Biosciences alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Enochian Biosciences
Employees

Enochian Biosciences, Inc. (NASDAQ:ENOB): Employee count
Aug 2023	22
Sep 2023	22
Oct 2023	22
Nov 2023	22
Dec 2023	22
Jan 2024	22
Feb 2024	22
Mar 2024	22
Apr 2024	22
May 2024	22
Jun 2024	22
Jul 2024	22

Enochian Biosciences
Hedge Funds Holdings Q1 2023

18.40% -19.70%

of ENOB is owned by hedge funds

25 -14

hedge funds hold ENOB stock

1.75M -1.87M

shares is hold by hedge funds

ENOB hedge funds holdings changes

Enochian Biosciences
Insider Trading

Enochian Biosciences, Inc. (NASDAQ:ENOB): Insider trades (number of shares)
Period	Buy	Sel
Feb 2022	0	6798
Mar 2022	0	1927
May 2022	253493	253493

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	18 May 2022	GUMRUKCU SERHAT 10 percent owner 10 percent owner	Common Stock	128,493	$8	$1,027,944
Sale	18 May 2022	GUMRUKCU SERHAT 10 percent owner 10 percent owner	Common Stock	125,000	$8	$1,000,000
Purchase	18 May 2022	SINDLEV RENE director, 10 percent owner director, 10 percent owner	Common Stock	128,493	$8	$1,027,944
Purchase	18 May 2022	SINDLEV RENE director, 10 percent owner director, 10 percent owner	Common Stock	125,000	$8	$1,000,000
Sale	22 Mar 2022	SANDLER CARL FOREST director, 10 percent owner director, 10 percent owner	Common Stock	1,927	$9.06	$17,459
Sale	23 Feb 2022	SANDLER CARL FOREST director, 10 percent owner director, 10 percent owner	Common Stock	6	$9	$54
Sale	18 Feb 2022	SANDLER CARL FOREST director, 10 percent owner director, 10 percent owner	Common Stock	6,792	$9.03	$61,345
Option	7 Jan 2020	PUCHE LUISA officer: Chief Fi..	Common Stock	5,000	N/A	N/A
Option	7 Jan 2020	PUCHE LUISA officer: Chief Fi..	Restricted Stock Units	5,000	N/A	N/A
Purchase	4 Jun 2019	SINDLEV RENE director, 10 percent owner director, 10 percent owner	Common Stock	31,500	$6.7	$211,050

ENOB insider trading transactions

Enochian Biosciences
Executives

Insider	Age	Compensation
Dr. Mark R. Dybul M.D. (1963) Chief Executive Officer & Director	62	$430,000
Ms. Luisa Puche (1964) Chief Financial Officer & Corporation Sec.	61	$275,000
Ms. Evelyn D'An (1963) Consultant	62	$63,520

Enochian Biosciences
Latest News

Monday, 17 July 2023
07:29	3 Doomed Biotech Stocks Destined for Disaster
Wednesday, 1 June 2022
15:32	'Murder-For-Hire Conspiracy': Why Enochian Biosciences Stock Is Plunging	Benzinga
Thursday, 26 May 2022
17:30	ENOB Stock Gains 20% Following Founder Arrest, Hindenburg Short	InvestorPlace
Wednesday, 25 May 2022
17:31	6 Stocks Halted In Wednesday's Session: Here's Why	Benzinga
Monday, 18 October 2021
08:33	ENOB Stock: Why The Price Increased Today	Pulse2
07:00	Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 month	GlobeNewsWire
Friday, 15 October 2021
18:00	Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity	GlobeNewsWire
Tuesday, 12 October 2021
18:00	Fireside Chat with Enochian BioSciences' CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference	GlobeNewsWire
Monday, 27 September 2021
07:00	Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection	GlobeNewsWire
Monday, 30 August 2021
07:00	Distinguished Scientific and Public Health Leaders to Join Enochian BioSciences' Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19 and Influenza Variants	GlobeNewsWire
Monday, 23 August 2021
10:18	Distinguished Scientific and Clinical Leader to Join Enochian BioSciences' Hepatitis B Cure Scientific Advisory Board	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 26 Jun 2021

Enochian Biosciences: A Follow Through For An HIV Cure

Frequently Asked Questions (FAQ)

When is Enochian Biosciences's next earnings date?

Unfortunately, Enochian Biosciences's (ENOB) next earnings date is currently unknown.
Does Enochian Biosciences pay dividends?

No, Enochian Biosciences does not pay dividends.
How much money does Enochian Biosciences make?

Enochian Biosciences has a market capitalization of 45.38M.
What is Enochian Biosciences's stock symbol?

Enochian Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "ENOB".
What is Enochian Biosciences's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Enochian Biosciences?

Shares of Enochian Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Enochian Biosciences's key executives?
Enochian Biosciences's management team includes the following people:
- Dr. Mark R. Dybul M.D. Chief Executive Officer & Director(age: 62, pay: $430,000)
- Ms. Luisa Puche Chief Financial Officer & Corporation Sec.(age: 61, pay: $275,000)
- Ms. Evelyn D'An Consultant(age: 62, pay: $63,520)
How many employees does Enochian Biosciences have?

As Jul 2024, Enochian Biosciences employs 22 workers.
When Enochian Biosciences went public?

Enochian Biosciences, Inc. is publicly traded company for more then 7 years since IPO on 7 Feb 2018.
What is Enochian Biosciences's official website?

The official website for Enochian Biosciences is enochianbio.com.
Where are Enochian Biosciences's headquarters?

Enochian Biosciences is headquartered at Century City Medical Plaza, Los Angeles, CA.
How can i contact Enochian Biosciences?

Enochian Biosciences's mailing address is Century City Medical Plaza, Los Angeles, CA and company can be reached via phone at +30 59181980.

Enochian Biosciences, Inc.

enochianbio.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

+30 59181980

Century City Medical Plaza
Los Angeles, CA 90067-2012

CIK: 0001527728
ISIN: US29350E1047
CUSIP: 29350E104